Trial Profile

A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arformoterol (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms LSSS
Sponsors Sunovion Pharmaceuticals

Most Recent Events

20 Dec 2016 Results assessing changes in health status after adding arformoterol tartrate or placebo to patients treatment regimens, published in the Clinical Therapeutics journal.
16 May 2016 Post-hoc analyses results published in the Media Release
04 May 2016 Post-hoc analyses presented at the 2016 American Thoracic Society (ATS) International Conference, according to a Sunovion Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com